ACW.ASX: ACW confirms eligibility for further $1.9m RDTI

ACW confirms eligibility for further $1.9m RDTI

Stock	Actinogen Medical Ltd (ACW.ASX)
Release Time	20 Oct 2025, 3:52 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Actinogen receives $1.9m R&D rebate for overseas activities

Key Points

Actinogen receives Advance Overseas Finding approval from ATO
Entitles the company to a further $1.9m R&D tax incentive rebate
Total FY25 RDTI rebate now $7.4m, supporting Alzheimer's trial progress

Full Summary

Actinogen Medical has received a certificate confirming an Advance Overseas Finding (AOF) for certain overseas research and development activities undertaken during the 2025 financial year. This AOF approval allows the company to submit an amendment to its FY25 Income Tax Return with the ATO, which will entitle it to a further research and development tax incentive (RDTI) rebate of $1,874,143. Aggregating the initial $5,489,600 RDTI rebate announced on 15 October 2025, the total FY25 RDTI rebate received by Actinogen will be $7,363,743. The RDTI is an important part of the company's ongoing sources of funds as it rapidly approaches key milestones in its Alzheimer's phase 2b/3 clinical trial, with an interim analysis in January 2026 and topline final results anticipated in mid Q4 2026.